No Data
Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
In the latest quarter, 4 analysts provided ratings for Lyra Therapeutics (NASDAQ:LYRA), showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table below illus
Cantor Fitzgerald Reiterates Overweight on Lyra Therapeutics
Cantor Fitzgerald analyst Louise Chen reiterates Lyra Therapeutics with a Overweight.
Lyra Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/20/2024 — Cantor Fitzgerald Reiterates → Overweight 05/07/2024 666.28% HC Wainwright & Co. → $2 Downgr
Express News | Lyra Therapeutics: Expects That the Majority of Charges Related to Workforce Reduction Will Be Incurred in the Second Quarter of 2024
Express News | Lyra Therapeutics:Estimates That It Will Incur Charges of About $3.9 to $4.1 Million in Connection With the Workforce Reduction
Lyra Therapeutics Reduces Workforce to Extend Cash Runway
Lyra Therapeutics (LYRA) said Tuesday it is cutting 87 jobs, or about 75% of its workforce, along with other measures to extend its cash runway into 2026. Lyra said it has stopped manufacturing and co